Dianthus

ArgenX

This company develops and commercialises antibody-based therapies to treat patients suffering from severe autoimmune diseases and cancer.

Re-Aim Therapeutics

This early-stage biotechnology company develops antibody-based therapies that target and deplete disease-causing cells to treat patients with autoimmune and inflammatory disorders.

Candid Therapeutics

This clinical-stage biotechnology company develops T-cell engager antibodies for patients with autoimmune and inflammatory diseases.

Clim Bio

This biotechnology company develops antibody-based medicines for patients with immune-mediated diseases such as lupus and IgA nephropathy.

APLS

This biopharmaceutical company develops complement-based therapies to treat autoimmune and inflammatory diseases for patients with conditions like paroxysmal nocturnal haemoglobinuria and geographic atrophy.

SciRhom

This biopharmaceutical company develops monoclonal antibodies targeting iRhom2 to treat patients with autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease.

True North Therapeutics

This biotechnology company develops monoclonal antibodies targeting the complement system to treat patients with rare blood, kidney and skin diseases.

Bambusa Therapeutics

The company develops bispecific antibodies for patients with immunological and inflammatory disorders.